Expert Review of Clinical Immunology最新文献_第3页

Guidance for stem cell therapy for juvenile systemic sclerosis patients. 青少年系统性硬化症患者干细胞治疗指南。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-03-24 DOI: 10.1080/1744666X.2025.2474216

Ivan Foeldvari, Kathryn S Torok, Juliana Silva, Christopher P Denton, Jörg Henes, Paulina Horvei, Franziska Rosser, Catherine H Orteu, Suzanne C Li, Clare E Pain, Tamás Constantin, Patricia Costa-Reis, Megan L Curran, Maurizio Cutolo, Bernd Hinrichs, Kim Fligelstone, Susan Maillard, Pia Moinzadeh, Clarissa Pilkington, Linda Schraven, Vanessa Smith

{"title":"Guidance for stem cell therapy for juvenile systemic sclerosis patients.","authors":"Ivan Foeldvari, Kathryn S Torok, Juliana Silva, Christopher P Denton, Jörg Henes, Paulina Horvei, Franziska Rosser, Catherine H Orteu, Suzanne C Li, Clare E Pain, Tamás Constantin, Patricia Costa-Reis, Megan L Curran, Maurizio Cutolo, Bernd Hinrichs, Kim Fligelstone, Susan Maillard, Pia Moinzadeh, Clarissa Pilkington, Linda Schraven, Vanessa Smith","doi":"10.1080/1744666X.2025.2474216","DOIUrl":"10.1080/1744666X.2025.2474216","url":null,"abstract":"Introduction: Autologous stem cell transplantation (ASCT) and cellular therapies (CTs) are emerging therapeutic options for both adult and juvenile-onset systemic sclerosis (jSSc) patients. However, most efficacy data are derived from adult studies, and it remains unclear whether adult stem cell transplant criteria are fully applicable to pediatric patients with jSSc. Given pediatric patients' unique potential for recovery and tissue remodeling, the stringent criteria used in adults need adaptation for children.Areas covered: We reviewed the current data on indications, patient selection, and outcomes of ASCT and CTs in both adult and pediatric patients with systemic sclerosis. At a multidisciplinary expert workshop held in Hamburg, Germany, in December 2023, we developed consensus guidance on when to consider ASCT and cellular therapies in jSSc.Expert opinion: HSCT and CT hold promise as treatment options for jSSc. Our proposed guidance aims to standardize inclusion criteria globally, enhancing comparability of outcomes across future procedures. Establishing consistent inclusion/exclusion criteria and transplant protocols will enable better data collection, interpretation, and ultimately improve outcomes and care for jSSc patients.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"435-450"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study. 候选tocilizumab生物类似药CT-P47在类风湿性关节炎患者中通过自动注射器和预填充注射器自我给药的可用性、有效性和安全性：一项单臂、开放标签、3期研究

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-01-15 DOI: 10.1080/1744666X.2025.2451215

Gerd Burmester, Piotr Adrian Klimiuk, Jakub Trefler, Janusz Jaworski, SungHyun Kim, YunJu Bae, DaBee Jeon, HyunSeung Lee, JiYoung Jang, ChanKyoung Hwang, HoJae Lee, Josef S Smolen

{"title":"Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.","authors":"Gerd Burmester, Piotr Adrian Klimiuk, Jakub Trefler, Janusz Jaworski, SungHyun Kim, YunJu Bae, DaBee Jeon, HyunSeung Lee, JiYoung Jang, ChanKyoung Hwang, HoJae Lee, Josef S Smolen","doi":"10.1080/1744666X.2025.2451215","DOIUrl":"10.1080/1744666X.2025.2451215","url":null,"abstract":"Background: CT-P47 is a candidate tocilizumab biosimilar that is currently in clinical development. We assessed the usability of CT-P47 self-administration via auto-injector (AI) in patients with rheumatoid arthritis (RA).Research design and methods: This was a 12-week, single-arm, open-label, multiple-dose, Phase 3 study. Patients self-injected CT-P47 (162 mg/0.9 mL) via AI at Weeks 0 and 2, and then every other week via pre-filled syringe (PFS) from Week 4 through Week 10. The primary endpoint was POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 2. Efficacy, safety, and immunogenicity were also assessed.Results: Thirty-three patients were enrolled. Mean scores for all POST-SIAQ domains at Week 2 exceeded 8, except for 'self-confidence' (7.11) and 'satisfaction with self-injection' (7.98), indicating positive patient experiences with CT-P47 AI. Furthermore, an observer-completed checklist found that all patients successfully followed the required steps for self-injection. Efficacy, assessed by Disease Activity Score in 28 joints and its components, showed improvements from baseline to Week 12. No new safety signals were observed; the most common adverse events were leukopenia, neutropenia, and injection-site reaction, each occurring in 3 (9.1%) patients.Conclusions: CT-P47 self-administered using an AI showed successful usability in patients with moderate-to-severe RA.Trial registration: ClinicalTrials.gov identifier: NCT05725434.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"521-529"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine. 遗传多态性影响用于治疗炎症性肠病的药物的临床药理学：多组学精确医学方法的先驱。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-02-05 DOI: 10.1080/1744666X.2025.2461584

Matthew B Stanton, Mark A Solinski, Stephen B Hanauer

{"title":"Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine.","authors":"Matthew B Stanton, Mark A Solinski, Stephen B Hanauer","doi":"10.1080/1744666X.2025.2461584","DOIUrl":"10.1080/1744666X.2025.2461584","url":null,"abstract":"Introduction: Inflammatory bowel diseases (IBDs), comprised of ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of the gastrointestinal tract. Clinicians and patients must vigilantly manage these complex diseases over the course of the patient's lifetime to mitigate risks of the disease, surgical complications, progression to neoplasia, and complications from medical or surgical therapies. Over the past several decades, the armamentarium of IBD therapeutics has expanded; now with biologics and advanced small molecules complementing conventional drugs such as aminosalicylates, corticosteroids and thiopurines. Significant attention has been paid to the potential of precision medicine to assist clinicians in tailoring therapeutics based on patients' genetic signatures to maximize therapeutic benefit while minimizing adverse effects.Areas covered: In this paper, we review the published literature on genetic polymorphisms relevant to each class of IBD therapeutics.Expert opinion: Finally, we envision a paradigm shift in IBD research toward an omics-based network analysis approach. Through global collaboration, organization and goal setting, we predict the next decade of IBD research will revolutionize existing disease frameworks by developing precise molecular diagnoses, validated biomarkers, predictive models and novel molecularly targeted therapeutics.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"461-472"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical treatments in special populations of atopic dermatitis - Chinese perspective. 特应性皮炎特殊人群的局部治疗——中国视角。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-03-05 DOI: 10.1080/1744666X.2025.2473726

Hongyu Ruan, Xiaoxia Zhu, Suling Xu, Qiongyan Zhou, Feng Yang, Guixiu Li

{"title":"Topical treatments in special populations of atopic dermatitis - Chinese perspective.","authors":"Hongyu Ruan, Xiaoxia Zhu, Suling Xu, Qiongyan Zhou, Feng Yang, Guixiu Li","doi":"10.1080/1744666X.2025.2473726","DOIUrl":"10.1080/1744666X.2025.2473726","url":null,"abstract":"Introduction: Atopic Dermatitis (AD) is a common chronic, recurrent inflammatory skin disease, characterized mainly by polymorphic skin lesions and severe itching, significantly affecting patients' physical and mental health. The pathogenesis of AD is complex, involving multiple factors such as genetics, environment, immunity, and microbiota. In terms of treatment, traditional systemic therapies are gradually being replaced by more targeted molecular immunotherapies, and the range of topical medications has become more diverse. However, research on AD treatment in special populations, such as children, pregnant women, lactating women, and the elderly, remains relatively limited.Areas covered: This review aims to discuss the research progress on topical treatments for AD in special populations both domestically and internationally, with a focus on personalized treatment approaches. It covers many aspects such as hormones, antimicrobial drugs, small molecule drugs, nanotechnology and microecological therapies, and proposes personalized treatments for each group and problems that need to be solved by current research.Expert opinion: Special populations have unique physiological characteristics, which may lead to different responses to topical medications. Therefore, personalized treatment strategies are especially important in this context. As insights into pathogenesis evolves, the novel therapies are on the rise, holding promise for more targeted treatment approaches.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"425-434"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toward a personalized therapy of still's disease based on immunologic endotypes: a narrative review. 基于免疫内型的斯蒂尔氏病个体化治疗：叙述性回顾。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-02-11 DOI: 10.1080/1744666X.2025.2465406

Po-Ku Chen, Shiow-Jiuan Wey, Der-Yuan Chen

{"title":"Toward a personalized therapy of still's disease based on immunologic endotypes: a narrative review.","authors":"Po-Ku Chen, Shiow-Jiuan Wey, Der-Yuan Chen","doi":"10.1080/1744666X.2025.2465406","DOIUrl":"10.1080/1744666X.2025.2465406","url":null,"abstract":"Introduction: Accumulative evidence indicates that both innate and adaptive immunity are involved in pathogenesis of Still's disease, an autoinflammatory disease. With Increasing insights into the pathogenesis of Still's disease coupled with the availability of emerging targeted therapeutics, it may be the unmet need for personalizing therapy and achieving a treat-to-target goal. We aim to summarize the available evidence regarding immunopathogenesis of Still's disease and therapeutic strategies based on immunologic endotypes.Areas covered: We searched MEDLINE database using the PubMed interface and reviewed relevant English-language literature from 1971 to 2024. This review focuses on the existing evidence on pathophysiology and immunological endotypes of Still's disease and their implications for personalized strategies for patients with this disease.Expert opinion: Targeting the complex immunopathogenesis of Still's disease, emerging new agents are available for treatment, including biologic disease-modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) such as Janus kinase inhibitors (JAKi). According to the updated evidence, meta-analyses, and recommendations, we propose a flow chart emphasizing personalized therapeutic strategies based on immunological endotypes. Hopefully, the therapeutic strategy might help guide the optimal selection of b/tsDMARDs to achieve a 'treat-to-target' goal in Still's disease. This proposed flow chart will be updated as newer evidence emerges.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"401-412"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

French Guiana and AGS: a path to uncovering hidden clues. 法属圭亚那和AGS：一条发现隐藏线索的道路。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-03-10 DOI: 10.1080/1744666X.2025.2475984

Evrard Baduel, Magdalena Smilov, Loïc Epelboin

{"title":"French Guiana and AGS: a path to uncovering hidden clues.","authors":"Evrard Baduel, Magdalena Smilov, Loïc Epelboin","doi":"10.1080/1744666X.2025.2475984","DOIUrl":"10.1080/1744666X.2025.2475984","url":null,"abstract":"Introduction: This article is a narrative review exploring how research in French Guiana could unlock the mysteries surrounding Alpha-Gal Syndrome (AGS), a recently identified IgE-mediated allergy with delayed reactions to exposure to non-Catarrhine mammalian-derived products. Although fewer than 10 cases have been reported across Latin America, two case series involving 11 and 18 patients with AGS have been documented in French Guiana.Areas covered: This article discusses risk factors such as ethnicity, prior pathogen-induced immunization to α-Gal, vectors responsible for AGS, their environment and ecosystems, observed phenotypes, and therapeutic implications for sensitized individuals. Literature research was based on PubMed between 12/2023 and 08/2024, using: α-Gal/Alpha-1,3-Galactose/galactose-α 1,3-galactose/Red meat allergy/Mammalian meat allergy/Alpha gal syndrome/Antivipmyn. Grey literature from French Guiana were obtained from Prof. Loïc Epelboin.Expert opinion: Advancing AGS research in French Guiana could yield valuable epidemiological insights, as existing data predominantly stem from European, North American, Australian, and Japanese contexts - regions with comparatively lower diversity in tick species, their mammalian hosts, associated pathogens, and parasitic infestations. Additionally, French Guiana presents unique therapeutic scenarios, such as Viperidae envenomation and transfusions under inventory constraints, that merit further investigation.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"507-519"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives. 生物制剂和小分子：儿童和青少年特应性皮炎治疗的再进化。当前的艺术状态和未来的展望。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-01-20 DOI: 10.1080/1744666X.2025.2452247

Enza D'Auria, Cristiana Indolfi, Miriam Acunzo, Giulio Dinardo, Pasquale Comberiati, Diego Peroni, Gian Vincenzo Zuccotti, Michele Miraglia Del Giudice

{"title":"Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives.","authors":"Enza D'Auria, Cristiana Indolfi, Miriam Acunzo, Giulio Dinardo, Pasquale Comberiati, Diego Peroni, Gian Vincenzo Zuccotti, Michele Miraglia Del Giudice","doi":"10.1080/1744666X.2025.2452247","DOIUrl":"10.1080/1744666X.2025.2452247","url":null,"abstract":"Introduction: In recent years, the understanding of atopic dermatitis (AD) pathogenetic mechanisms has expanded, and now it is recognized that Th2 immune axis dysregulation is pivotal to AD pathogenesis. The advent of biological drugs and small molecules has marked a revolution in the treatment of AD. Dupilumab, targeting IL-4 and IL-13, has been the first to demonstrate efficacy in treating moderate to severe AD by modulating type-2 inflammation pathways. Increasing knowledge of different immune axis and cytokines has fueled the development of new biologics and small molecules. JAK inhibitors, which target the JAK-STAT pathway, involved in cytokine signaling, represent a promising novel therapeutic strategy, enlarging the treatment options for moderate to severe atopic dermatitis.Areas covered: This comprehensive review aims to provide an updated and critical overview of the drugs currently in use and under investigation for the treatment of moderate to severe AD in children and adolescents, along with addressing the unmet needs and future research perspectives.Expert opinion: Biologics and small molecules offer the promise to enlarge the arsenal options for the treatment of AD. Since the patients' response to biologics depends on AD pheno-endotype, choosing the right biologic is crucial for ensuring therapy success.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"493-505"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological therapy in chronic rhinosinusitis with nasal polyps. 慢性鼻炎伴鼻息肉的生物疗法。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-01-31 DOI: 10.1080/1744666X.2025.2459929

Zeyi Jin, Bing Yan, Luo Zhang, Chengshuo Wang

{"title":"Biological therapy in chronic rhinosinusitis with nasal polyps.","authors":"Zeyi Jin, Bing Yan, Luo Zhang, Chengshuo Wang","doi":"10.1080/1744666X.2025.2459929","DOIUrl":"10.1080/1744666X.2025.2459929","url":null,"abstract":"Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease. High proportions of patients with CRSwNP characterized by type 2 inflammation fail to gain adequate control with conventional treatment. The application of biologics in clinics and assessments of novel biologics in clinical trials are blooming in expectations to fulfill the unmet medical needs of patients with CRSwNP with type 2 inflammation.Areas covered: After an extensive search of PubMed, Medline, and EMBASE for the most recent evidence, we thoroughly summarize current advances in biological therapies for treating patients with CRSwNP.Expert opinion: In recent years, biological therapy has been in the spotlight in clinical studies on CRSwNP. Biologics have proven to be efficacious in reducing nasal polyp size, alleviating CRSwNP-related symptoms, improving quality of life, and reducing the need for systemic corticosteroids or endoscopic sinus surgery for nasal polyps. The considerable efficacy and safety profile of biologics has offered patients with refractory CRSwNP another treatment option. However, some concerns remain to be addressed. Aspects such as the position of biological therapy in the management of CRSwNP, traits of patients suitable for certain biologics, etc. necessitate efforts to elucidate these unknowns in order to provide patients with tailored therapy.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"473-492"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT). 2型炎症：使用Web-Delphi和决策会议（INFLAT2-PT）的葡萄牙共识。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2025-01-07 DOI: 10.1080/1744666X.2024.2448990

Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa

{"title":"Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT).","authors":"Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, João Gonçalves, João Carlos Ribeiro, Luís Taborda-Barata, Helena Farinha, Pedro Escada, Samuel Fernandes, Luís Soares-de-Almeida, Maria João Paiva-Lopes, Cláudia Chaves Loureiro, Isabel Lourinho, João A Fonseca, Marta Drummond, Rui Tato Marinho, João Bana E Costa, António Vaz Carneiro, Carlos A Bana E Costa","doi":"10.1080/1744666X.2024.2448990","DOIUrl":"10.1080/1744666X.2024.2448990","url":null,"abstract":"Objectives: Atopic/allergic diseases impose a growing burden on public health, affecting millions of patients worldwide. The main objective of this study was to develop a national expert consensus on relevant clinical questions related to type 2 inflammation.Methods: We conducted: a comprehensive literature review with a qualitative analysis to identify the most repeated themes on the overlap of conditions; a modified 3-round Web-Delphi (or e-Delphi); and a final online decision conference.Results: We included 51 studies. Following three Web-Delphi rounds, we ended up with 30 statements with a 76% overall full agreement rate, 16% agreement, 2% disagreement, and 0% full disagreement. The decision conference enabled adjustments, and the expert panel agreed unanimously on the final set of statements. The consensus used evidence synthesis, Web-Delphi, and decision conference to produce 30 statements on type 2 inflammation as a driver for multimorbidity in asthma, certain rhinitis phenotypes, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis grouped under five domains in underlying pathophysiology, multimorbidity, diagnosis and management, multidisciplinary management, and impact on mental health.Conclusion: We expect the first Portuguese expert consensus INFLAT2-PT to promote understanding of type 2 inflammation diseases, multidisciplinary care, integrated care pathways, future research, and inform health authorities.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"377-391"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in tumor immunotherapy targeting macrophages. 靶向巨噬细胞的肿瘤免疫治疗研究进展。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-03-01 Epub Date: 2024-12-11 DOI: 10.1080/1744666X.2024.2438721

Binrui Shi, Meng Du, Zhiyi Chen

{"title":"Advances in tumor immunotherapy targeting macrophages.","authors":"Binrui Shi, Meng Du, Zhiyi Chen","doi":"10.1080/1744666X.2024.2438721","DOIUrl":"10.1080/1744666X.2024.2438721","url":null,"abstract":"Introduction: In recent years, immunotherapy has shown significant therapeutic potential in patients with advanced tumors. However, only a small number of individuals benefit, mainly due to the tumor microenvironment (TME), which provides conditions for the development of tumors. Macrophages in TME, known as tumor-associated macrophages (TAM), are mainly divided into M1 anti-tumor and M2 pro-tumor phenotypes, which play a regulatory role in various stages of tumorigenesis, promote tumorigenesis and metastasis, and cause immunotherapy resistance.Areas covered: This review focuses on research strategies and preclinical/clinical research progress in translating TAM into antitumor phenotype by referring to the PubMed database for five years. These include small molecule chemotherapy drug development, metabolic regulation, gene editing, physical stimulation, nanotechnology-mediated combination therapy strategies, and chimeric antigen receptor-based immunotherapy.Expert opinion: It is necessary to explore the surface-specific receptors and cell signaling pathways of TAM further to improve the specificity and targeting of drugs and to strengthen research in the field of probes that can monitor changes in TAM in real time. In addition, the physical stimulation polarization strategy has the advantages of being noninvasive, economical, and stable and will have excellent clinical transformation value in the future.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"259-276"},"PeriodicalIF":3.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0